Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.66 |
| ▸ | TEC | P42680 | 1/20 | 0.66 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.66 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.66 |
| ▸ | BTK | Q06187 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.66 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264546 | 0.89 | EGFR (0.58) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30264543 | 0.88 | EGFR (0.57) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3390788 | 0.86 | EGFR (0.84) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30264675 | 0.86 | EGFR (0.78) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30264566 | 0.85 | EGFR (0.73) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30264513 | 0.85 | EGFR (0.75) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3420438 | 0.85 | EGFR (0.77) | EGFRERBB2 | |
| SCHEMBL30264569 | 0.85 | EGFR (0.77) | EGFRERBB2 | |
| SCHEMBL3394863 | 0.85 | EGFR (0.85) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30264685 | 0.85 | EGFR (0.53) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | EGFR 1/4885ERBB2 3/4885RIPK2 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.